German biotech firm BioNTech (22UAy.DE), opens new tab on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer (PFE.N), opens new tab.
The company’s quarterly net loss came in at 387 million euros, an improvement over a net loss of 808 million in the year-earlier period, which at the time was burdened by provisions for a settlement with the U.S. National Institutes of Health over vaccine royalty payments.
Lower operating expenses also helped reduce the second-quarter loss, it added.
BioNTech reiterated its guidance for 2025 revenues of 1.7 billion to 2.2 billion euros, down from 2.75 billion last year.
BioNTech in June agreed to acquire domestic peer CureVac (5CV.DE), opens new tab in a $1.25 billion share deal, boosting its work on new mRNA-based cancer treatments and quelling patent litigation brought by the takeover target.
That was shortly after Bristol Myers Squibb (BMY.N), opens new tab agreed to pay up to $11.1 billion for rights to jointly develop BioNTech’s next-generation cancer immunotherapy.
